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Abstract
Enterotoxigenic Escherichia coli (ETEC) are major food-borne pathogens responsible for traveler’s diarrhea. The production of
adhesins and the secretion of enterotoxins constitute the major virulence traits of the bacteria. Treatments are mainly symptomatic
and can involve antibiotherapy. However, given the rise of antibiotic resistance worldwide, there is an urgent need for the
development of new preventive strategies for the control of ETEC infections. Among them, a promising approach is the use
of probiotics. The aim of this study was to investigate, using complementary in vitro and in vivo approaches, the inhibitory
potential of the yeast Saccharomyces cerevisiae CNCM I-3856 against the human ETEC reference strain H10407. In conven-
tional culture media, S. cerevisiae significantly reduced ETEC growth and toxin production. The yeast also inhibited bacterial
adhesion to mucin-agar and intestinal Caco-2/TC7 cells in a dose-dependent manner. Lastly, pre-treatment with S. cerevisiae
inhibited interleukin-8 production by ETEC-infected intestinal cells. In streptomycin-treated mice, the probiotic yeast decreased
bacterial colonization, mainly in the ileum, the main site of ETEC pathogenesis. For the first time, this study shows that the
probiotic yeast S. cerevisiae CNCM I-3856 can exert an anti-infectious activity against a human ETEC strain through a multi-
targeted approach, including inhibition of bacterial growth and toxin production, reduction of bacterial adhesion to mucins and
intestinal epithelial cells, and suppression of ETEC-induced inflammation. Interestingly, the highest activity was obtained with a
prophylactic treatment. Further studies will aim to assess the effect of the yeast on ETEC survival and virulence under human
simulated digestive conditions.
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Introduction
The food- and water-borne pathogen enterotoxigenic
Escherichia coli (ETEC) is responsible for hundreds of
millions of diarrheal episodes worldwide in people visiting
endemic countries (travelers’ diarrhea) and in infant under
5 years of age living in low-income countries where sani-
tation is poor (Kotloff et al. 2013; de la Cabada Bauche and
DuPont 2011). In humans, ETEC infection is characterized
by two major virulence traits which are (i) the adhesion of
the bacteria to epithelial cells of the small intestine orches-
trated by fimbrial or non-fimbrial adhesin colonization fac-
tors (CFs) and (ii) the production of heat-labile (LT) and/or
heat-stable (ST) enterotoxins leading to hypersecretion of
H2O and Cl
− at the root of watery cholera-like diarrhea
(Qadri et al. 2005; Turner et al. 2006). Following travelers’
diarrhea, persistent changes in gastrointestinal function
may occur and extend to post-infectious (PI) irritable bow-
el syndrome (IBS) (Spiller and Garsed 2009; Connor and
Riddle 2013).
The treatment of diarrheal disease due to ETEC is mainly
symptomatic with oral rehydration and use of antimotility
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agents. Antimicrobials are of definite benefit in particular in
the treatment of traveler’s diarrhea, but their use is limited by
the associated cost, common adverse effects, and raise in an-
tibiotic resistance worldwide. Non-antibiotic alternative strat-
egies are then widely encouraged by the European Union and
World Health Organization (CDC 2014). Additionally, there is
yet no commercially available prophylactic treatment (in par-
ticular, no vaccine) that specifically addresses ETEC infec-
tions or PI-IBS. Among promising solutions, strategies using
probiotic microorganisms are an extensive field of research
(Roussel et al. 2017). The internationally endorsed definition
of probiotics is BLivemicroorganisms that, when administered
in adequate amounts, confer a health benefit on the host^ (Hill
et al. 2014). A large panel of strains has been acknowledged as
probiotics, including lactic acid bacteria from Lactobacillus
and Bifidobacterium genera, and Saccharomyces yeast strains.
Among them, Saccharomyces cerevisiae CNCM I-3856
has already recognized probiotic properties. The strain
displayed beneficial effects against enteric E. coli pathogens,
such as enterohemorrhagic E. coli (EHEC) or adherent inva-
sive E. coli (AIEC). When co-administered with EHEC
O157:H7, this probiotic yeast significantly reduced bacterial
growth observed in the distal part of the human small intes-
tine, as simulated by the TNO GastroIntestinal Model (TIM)
(Etienne Mesmin et al. 2011). Thévenot et al. (2015) also
demonstrated that S. cerevisiae CNCM I-3856 inhibited
Shiga toxin gene expression under human simulated colonic
conditions and EHEC O157:H7 interactions with intestinal
Peyer’s patches and subsequent hemorrhagic lesions in mice.
In addition, the probiotic yeast reduced colonization, de-
creased pro-inflammatory cytokine production, and prevented
colitis in AIEC-infected mice (Sivignon et al. 2015). Lastly, in
clinical studies, S. cerevisiaeCNCM I-3856 has been reported
to benefit IBS symptoms through reduction of abdominal
pain, bloating, and constipation (Pineton de Chambrun et al.
2015; Cayzeele-Decherf et al. 2017).
Therefore, it would be of high interest to investigate the
inhibitory potential of S. cerevisiae CNCM I-3856 against
the well-characterized human ETEC strain H10407 in order
to evaluate its ability to prevent travelers’ diarrhea but also
associated PI-IBS. Here, we report the use of complementary
in vitro and in vivo approaches to assess the antagonistic ef-
fects of the probiotic yeast against the human reference strain
ETEC H10407 and try to describe the underlying
mechanisms.
Materials and methods
Strains and growth conditions
The prototypical ETEC strain H10407 (LT+, ST+, CFA/I+,
EtpA+, EatA+, YghJ+, ATCC® 35401), serotype
O78:H11:K80, isolated in Bangladesh from a patient with a
cholera-like syndrome (Evans et al. 1977), was used in this
study. Then, spontaneous mutations in ETECH10407 that con-
fer resistance to streptomycin were selected onto Luria Bertani
(LB) agar BD Difco (Fisher, Waltham, USA) containing strep-
tomycin (1 mg/ml) (Sigma, St. Louis, USA). Bacterial growth
and adhesion to intestinal epithelial cells of the selected ETEC
StrR mutant were equivalent to those of the wild-type ETEC
strain.
ETEC wild type was routinely grown at 37 °C in LB or in
colonization factor antigen (CFA)media. For mouse infection,
ETEC StrR mutant was grown at 37 °C in LB broth with
streptomycin (25 μg/ml). ETEC and ETEC StrR mutant were
plated onto LB agar and LB agar supplemented with strepto-
mycin (25 μg/ml), respectively, and incubated at 37 °C for
24 h under aerobic conditions.
The probiotic yeast strain S. cerevisiae CNCM I-3856
(Lesaffre Human Care, Marcq-en-Baroeul, France) was sup-
plied in its active dried powder form. Before experiments,
yeasts were re-suspended in sterile saline water and mixed
with an ultra-Turrax yellow line (IKA, Rawang, Malaysia).
Yeasts were plated onto Sabouraud agar BD Difco (Fisher,
Waltham USA) with chloramphenicol (50 mg/l) (Sigma, St.
Louis, USA) and incubated at 30 °C for 48 h under aerobic
conditions.
Human intestinal cell lines
TC7 cells, a sub-clone obtained after a late passage of the
Caco-2 human colonic cell line (P-198), were provided from
the American Type Culture Condition (ATCC) and main-
tained in an atmosphere containing 5% CO2 at 37 °C in
DMEM (Dulbecco’s modified Eagle’s medium). The Caco-
2/TC7-polarized epithelial cell line, mimicking structurally
and functionally an intestinal barrier, has been previously rec-
ommended for its performance and reproducibility (Liévin-Le
Moal and Servin 2013). Cells were seeded in 24-well culture
plate at a density of 5 × 104 cells/well and incubated at 37 °C
for 14 days. Experiments were performed 14 days post-
seeding, after complete morphological and functional differ-
entiation of Caco-2/TC7 cells.
Co-cultures in LB media
In a first series of experiments (n = 3), ETEC H10407
(107 CFU/ml) and S. cerevisiae CNCM I-3856 were co-
cultured in LB broth media during 6 h at 37 °C in a rotary
shaker (80 rpm). Before co-culture phase, S. cerevisiae
(107 yeasts/ml) was pre-incubated in LB media for 3 h.
Samples were collected every 2 h to determine ETEC
culturability by plating onto LB and viability by PMA-qPCR
(propidium monoazide). Briefly, samples were stained with
50 μM PMA (Interchim, Montluçon, France) in the dark,
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incubated 5 min at room temperature, and exposed 15 min to
the blue light PMA-Lite LED Photolysis (Interchim,
Montluçon, France). Samples were then pelleted (1000g,
10 min, 4 °C) and stored at − 20 °C until DNA extractions that
were performed using the Smart Extract Kit SK-DNEX-100
(Eurogentec, Seraing, Belgium) according to the manufac-
turer’s instructions. The qPCR procedure was carried out using
the StepOnePlus Real Time PCR (ThermoFisher, Waltham,
USA) in a total reaction volume of 10 μl, containing 5 μl of
Takyon Low Rox Sybr Master Mix dTTP blue (Eurogentec,
Seraing, Belgium), 0.45 μl (10 μM) of primers encoding for
the 16S Enterobacteriaceae (F- CATGCCGCGTGTAT
GAAGAA, R- CGGGTAACGTCAATGAGCAAA)
(Huijsden et al. 2002), 3.1 μl milli-Q water, and 1 μl of tem-
plate DNA sample. Non-template control was 1 μl milli-Q
water. The PCRs were amplified by an initial denaturation step
at 95 °C for 5 min followed by 45 cycles of 95 °C (30 s), 60 °C
(30 s), and 72 °C (30 s).
In a second series of experiments (n = 3), LT toxin produc-
tion was measured after an overnight co-culture (14 h) of
ETEC and S. cerevisiae in LB broth media (37 °C, 80 rpm).
The yeast ability to remove LT toxin was also studied by
incubating the supernatant from an ETEC overnight culture
(containing LT toxin) with S. cerevisiae suspended into
phosphate-buffered saline (PBS) (14 h, 37 °C, 80 rpm). At
the end of assays, culture supernatants (centrifugation at
1000g, 15 min, 4 °C) were collected to measure the final LT
toxin concentrations and cell pellets from the co-culture ex-
periments were used to follow eltB gene expression. Control
experiments were performed in each condition without probi-
otic (n = 3).
Agglutination assays
Serial dilutions (from undiluted to 1/360) of an ETEC
H10407 bacterial suspension in PBS (107 CFU/ml) were
added in a 96-well plate (U bottom) at a final volume of
50 μl/well. A suspension of yeasts was prepared in PBS
(108 yeasts/ml) with or without α-D-mannose 1% (Sigma,
St. Louis, USA) and was distributed in each well (50 μl/
well). Microplates were shaken for 10 min at 300 rpm and
visually analyzed to determine the agglutination titer after
2 h incubation at room temperature. Agglutination titer was
determined according to the last bacterial dilution allowing
yeast agglutination. Agglutination assays in microplates
were completed by microscopic observations of aggluti-
nates. Co-culture of ETEC and yeasts (1:1), with or without
α-D-mannose 1%, was observed after 1-h incubation (37 °C,
45 rpm) by using the Axioskop phase contrast microscope at
a magnification × 1000 (Zeiss, Thornwood, USA). Negative
controls were performed without ETEC and all experiments
were performed in triplicate.
Mucin adhesion assay
Adhesion experiments were adapted from Tsilia et al. (2016).
Mucin-agar consisted of 5% porcine mucin type II (Sigma, St.
Louis, USA) and 1% bacteriological agar (Sigma, St. Louis,
USA). The pH level of mucin-agar was adjusted at 6.8 with
10 M NaOH to closely mimic small intestinal pH level. In the
pre-incubation phase, a suspension of S. cerevisiae CNCM I-
3856 (107 yeasts/ml) was added onto 12-wells plates contain-
ing 1.2 ml of autoclaved mucin-agar. Plates were incubated at
37 °C on a rotary shaker (45 rpm) for 1 h. Then, the infection
phase was started by adding ETEC H10407 (107 CFU/ml).
After 1 h co-incubation, non-adhered bacteria were removed
and each well was rinsed three times with PBS. Extraction of
adhered bacteria was mechanically performed by transferring
aseptically the whole mucin layer with a sterilized spatula in a
sterile bag containing 8.8 ml PBS. The mixture was homoge-
nized for 10min in a 400PBagMixer® (Interscience,Woburn,
USA). Non-adhered ETEC/S. cerevisiae and adhered
ETEC/S. cerevisiae extracted were quantified by plating.
Percentages of adherent bacteria or yeasts onto mucus were
calculated as follows: (X adhered to mucus)/(X adhered to mucus + X
lumen) × 100. Lumen represents the liquid part upon the mucus
layer with non-adhered bacteria. The experiments were per-
formed in triplicate and agar without mucin was used as neg-
ative control (NC).
In vitro digestions in the TIM model
In vitro digestions were performed in the TIM model (TNO
Triskelion, Zeist, Netherlands) which consists in four succes-
sive compartments simulating the human stomach and the three
parts of the small intestine (duodenum, jejunum, and ileum).
The TIM model integrates the main physicochemical parame-
ters of human digestion, such as body temperature, temporal
and longitudinal changes in gastric and intestinal pH levels,
peristaltic mixing and transport, gastric, biliary, and pancreatic
secretions, and passive absorption of small molecules and wa-
ter. This model has been already described in detail in previous
publications (Cordonnier et al. 2015; Roussel et al. 2016). The
TIM system was programmed to reproduce, based on in vivo
data, the digestive conditions observed in a healthy adult after
ingestion of a glass of water (Table 1). At the beginning of
digestion, a hydroxypropylmethylcellulose (HPMC) capsule
containing 2 × 109 yeasts S. cerevisiae CNCM I-3856
(Lesaffre Human Care, Marcq-en-Baroeul, France) was intro-
duced into the TIM stomach with a glass of mineral water
(initial concentration 107 yeasts/ml). In a first series of digestion
(n = 3), ileal effluents were collected on ice and pooled at 0–60,
60–120, 120–180, 180–240, and 240–300 min. Samples were
taken in each collection to evaluate by plating the yeast survival
rate during gastrointestinal passage. Results were expressed as
percentages of initial intake and were compared to those of a
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theoretical non-absorbable transit marker which models a
100% survival rate. In a second series of digestion, the overall
content of the ileal compartment was collected at 120-min di-
gestion for adhesion assays on intestinal Caco-2/TC7 cells.
Experiments on intestinal Caco-2/TC7 cells
In a first series of experiments (n = 3), Caco-2/TC7 cells were
infected at a multiplicity of infection (MOI) of 100. Different
concentrations of S. cerevisiae CNCM I-3856 were used: 105,
106, 5 × 106, and 107 yeasts/ml. Three modes of treatment
were tested for the probiotic yeasts: (i) pre-incubation, Caco-
2/TC7 cells were pre-treated for 3 h with yeasts then, they
were infected with ETEC bacteria in the presence of yeasts
for 3 h; (ii) co-incubation, ETEC and yeasts were co-
incubated for 3 h with intestinal cells and; (iii) post-incuba-
tion, Caco-2/TC7 cells were first infected with ETEC for 3 h,
non-adherent bacteria were eliminated by three washes with
PBS, and intestinal cells were further incubated with yeasts for
3 additional hours. At the end of experiments, Caco-2/TC7
cells were lysed with 1% Triton X-100 (Sigma, St. Louis,
USA) and serial dilutions were plated onto LB agar to deter-
mine the number of ETEC bacteria associated to the cells.
Control experiments (n = 3) were performed without yeast
(Bnot treated^) to determine the ETEC adhesion level to
Caco-2/TC7 cells (considered as 100%) and with yeast alone.
The effect of yeasts on ETEC adhesion was compared to that
of the non-treated condition and results were expressed in
percentages of residual adhesion.
In a second series of experiment (n = 3), Caco-2/TC7 cells
were pre-incubated with S. cerevisiae CNCM I-3856 (at dif-
ferent doses: 105, 106, and 107 yeasts/ml) before ETEC infec-
tion using a 3 h pre-incubation with yeast and 3-h infection at
MOI 100. At the end of experiments, cell supernatants
(centrifugation at 1000g, 15 min, 4 °C) were collected to mea-
sure the pro-inflammatory cytokine IL-8 secreted by the intes-
tinal cells and LT production by ETEC. Control experiments
(n = 3) were performed without probiotic (Bnot treated^) and
with non-infected cells (Bnot infected^).
In a third series of experiments (n = 3), digested yeasts
collected from the TIM ileal compartment were washed twice
in PBS (2500g, 15 min, 4 °C), numerated in Malassez cells,
and re-suspended in DMEM to obtain different cell concen-
trations (105, 106, 5 × 106, and 107 yeasts/well). Caco-2/TC7
cells were pre-incubated for 3 h with the different concentra-
tions of S. cerevisiae CNCM I-3856 before ETEC infection
(3 h at MOI 100). At the end of experiments, Caco-2/TC7
cells were treated as described above to determine the percent-
ages of adherent bacteria. Control experiments (n = 3) were
performed without probiotic (Bnot treated^) and with non-
digested S. cerevisiae that were washed or not.
Determination of eltB expression and LT production
Reverse transcription (RT)-PCR was used to follow eltB gene
expression. Total RNAs from overnight co-cultures in LBmedia
were extracted using TRIzol reagent (Fisher, Waltham, USA).
RNAs were reversely transcribed using the PrimeScript RT re-
agent kit (Takara Bio, Korea, Japan). qPCR was performed
using Takyon low Rox SYBR master mix (Eurogentec,
Seraing, Belgium) on a MxPro qPCR system (Agilent, Les
Ulis, France) with the primers eltB-F: GGCAGGCA
AAAGAGAAATGG and eltB-R: TCCTTCATCCTTTC
AATGGCT (Lothigius et al. 2008). Enterobacteriaceae rRNA
16S (16S-F: CATGCCGCGTGTATGAAGAA and 16S-R:
CGGGTAACGTCAATGAGCAAA) was used as the house-
keeping gene for quantification of mRNA expression
(Huijsdens et al. 2002). Fold-induction was calculated using
Table 1 Parameters of the TIM
system when simulating digestive
conditions of a healthy adult after
intake of a glass of water. A
power exponential equation (f =
1–2-(T/T1/2)
β where f represents
the fraction of water delivered,
T1/2 represents the half-time of
delivery, and β, a coefficient de-
scribing the shape of the curve,
was used for the computer control
of gastric and ileal deliveries in
the TIM
Parameters of in vitro
digestion of a glass of
water
Gastric
compartment
Duodenal compartment Jejunal
compartment
Ileal
compartment
pH from 6 (T0) to
1.5 (90 to
300 min)
Maintained at 6.4 Maintained at
6.9
Maintained at
7.2
Volume 200 ml (T0) 30 ml 115 ml 115 ml
Secretions (i) 130 U/min
of pepsin
(ii) 5 U/min of
lipase
(iii) HCl 0.3 M
if necessary
(i) 20 mg/min of bile salts (first
30 min of digestion) then
10 mg/min
(ii) 20 mg/min of pancreatic
juice 4 USP
(iii) NaHCO3 0.5 M if
necessary
(i) NaHCO3
0.5 M if
necessary
(i) NaHCO3
0.5 M if
necessary
Emptying time T1/2 = 15 min – –
T1/2 = 150 -
min
β coefficient β = 1 – – β = 2.4
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the cycle threshold (Ct) method as follows: ΔΔCt = (Ct target gene
−Ct housekeeping gene) at time t − (Ct target gene −Ct housekeeping gene)
at t0.
LT concentrations in supernatants from co-cultures in LB
media or Caco-2/TC7 cells were measured by enzyme-linked
immunosorbent assay (ELISA) according to the manufac-
turer’s instructions (human heat-labile enterotoxin B subunit
ELISA kit, MyBiosource, San Diego, USA). Optical density
was read at 450 nm using a multi-scan spectrum (Fisher,
Waltham, USA).
Interleukin-8 ELISA
Pro-inflammatory IL-8 cytokines were dosed in supernatants
from Caco-2/TC7 cells according to the manufacturer’s in-
structions (DuoSet ELISA, human CXCL8/IL-8 ref DY208,
RnD Systems, Minneapolis, USA). Optical density was read
at 450 nm using a multi-scan spectrum (Fisher, Waltham,
USA).
Mouse infection experiments and ethics statement
According to the validated murine model of small intestinal
colonization with ETEC fromAllen et al. (2006), five to seven
immunocompetent adult (5 to 7 weeks old) female mice from
the ICR (Institute of Cancer Research) were provided by
Charles River Laboratories (Ecully, France). Mice were
housed in specific pathogen-free conditions in the animal care
facility of the University of Clermont Auvergne (Clermont-
Ferrand, France). Animal protocols used in this study were
approved by the CEMEA Auvergne committee for ethical
issues (no. agreement 00730.02). Briefly, mice were forced-
fed with S. cerevisiae CNCM I-3856 (5 × 107 yeasts/day from
day 0 to day 3). At day 2, they were orally treated with 20 mg/
mouse of the broad-spectrum antibiotic streptomycin
(Euromedex, Souffelweyersheim, France) to disrupt normal
resident intestinal microbiota. At day 3, cimetidine (Sigma,
St. Louis, USA) was administered by intra-peritoneal injection
(50 mg/kg) to ablate gastric secretions. On the same day, 1 h
after the last administration of the probiotic, mice were orally
challenged with 108 CFU of StrR ETEC. Body weight was
measured at days 1 and 4. At day 4, mice were anesthetized
with isoflurane (Sigma, St. Louis, USA) and euthanized by
cervical dislocation. Bacterial colonization of fecal samples
and intestinal tissues was assessed at day 4. Fresh feces were
suspended in sterile saline solution and serial dilutions were
plated onto LB agar supplemented with streptomycin. Ileal
tissue (3-cm segment) and entire colon were collected, weight-
ed and cut longitudinally, washed, and homogenized in PBS
with an Ultra-Turrax before plating on streptomycin LB agar.
The amount of adherent bacteria was expressed in CFU/mg of
tissue.
Statistical analysis
Values are given as means ± standard deviation (SD) for
in vitro experiments (n = 3) and as medians and means ± stan-
dard errors of the means (SEM) for in vivo experiments (n = 5
to 7). Significant differences between treatments were tested
using a non-parametric Mann-Whitney test. Statistical analy-
sis was performed with R 3.3.2 and R studio. A probability
level of p < 0.05 was considered to be statistically different.
Results
S. cerevisiae CNCM I-3856 reduces ETEC H10407
growth and LT toxin concentrations in culture media
As the inhibitory properties of S. cerevisiae CNCM I-3856
against the human prototypical ETEC strain H10407 have
never been evaluated, the effect of the probiotic yeast on
ETEC growth and toxin production was first studied in con-
ventional culture media. When S. cerevisiae was pre-
incubated 3 h in LB media before ETEC inoculation, the pro-
biotic yeast induced a significant decrease in bacterial growth
(p < 0.01, n = 3), as assessed by plating (Fig. 1a) and con-
firmed by PMA-qPCR (data not shown). The highest inhibi-
tory effect was noticed at 4 h, with ETEC concentrations of
3.4 × 108 CFU/ml under probiotic treatment compared to
1.2 × 109 CFU/ml under control conditions. In addition, LT
toxin production and the expression of the corresponding
eltB gene were measured after an overnight culture of ETEC
H10407 when the probiotic was added or not. LT production
was significantly reduced with S. cerevisiae CNCM I-3856
with concentrations decreasing from 136 ± 31 pg/ml under
control conditions to 69 ± 8 pg/ml with probiotics (p < 0.01,
n = 3) (Fig. 1b on the left). This decrease in LT production was
associated to a removal by the yeast of LT toxin (p < 0.001,
n = 3) (Fig. 1b on the right) and to a reduction in eltB gene
expression (p = 0.063, n = 3) (Fig. 1c).
S. cerevisiae CNCM I-3856 directly interacts with ETEC
bacteria in a mannose-related manner
In a later step, the ability of the probiotic strain to directly
interact with ETEC through a trapping mechanism at the cell
surface called agglutination (Tiago et al. 2012) was investigat-
ed. S. cerevisiae CNCM I-3856 and ETEC H10407 were co-
incubated and agglutinates were macro- and microscopically
observed. Agglutination between probiotic yeast and ETEC
H10407 occurred until bacterial dilution of 1/24 (data not
shown). To further investigate the mechanisms of action, we
evaluated the effect of α-D-mannose, a major compound from
S. cerevisiae cell walls, on yeast-bacteria agglutination. In the
presence of 1%α-D-mannose, ETEC H10407 lost their ability
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Fig. 1 In vitro effect of S. cerevisiae CNCM I-3856 on ETEC growth,
toxin production, agglutination, and adhesion to mucin a ETEC H10407
growth in LB media (107 CFU/ml), as determined by plating, without
probiotic (black) or after 3 h pre-incubation with 107 yeasts/ml of S.
cerevisiae CNCM I-3856 (Sc) (grey). b On the left: LT toxin
production (in pg/ml) after an overnight culture of ETEC (black) or
ETEC + Sc (white) in LB media inoculated with 107 CFU/ml bacteria
and/or yeasts. The results were normalized with the number of viable cells
as determined by plating on LB; on the right: LT toxin concentration (in
pg/ml) in the supernatant from an ETEC culture treated or not with
107 CFU/ml Sc. c eltB gene expression (fold changes compared to the
initial time T0 set at 1) after an overnight culture of ETEC (black) or
ETEC + Sc (white) in LB media inoculated with 107 CFU/ml bacteria
and/or yeasts. d Microscopic observation of ETEC/Sc agglutinates after
1 h co-culture with or without 1%α-D-mannose (magnification × 1000). e
ETEC (107 CFU/ml) adhesion to mucin-agar layer without probiotic
(black) or after 1 h pre-incubation with 107 yeasts/ml Sc (white). Agar
without mucin was used as negative control (NC). The data represent the
means ± SD of three independent replicates. ETEC + Sc statistically
different from ETEC at p < 0.05 (*), p < 0.01 (**), or p < 0.001 (***)
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to agglutinate probiotic yeasts (Fig. 1d). These results suggest
that yeasts interact directly with ETEC bacteria in a mannose-
related manner.
Pre-incubation with S. cerevisiae CNCM I-3856
reduces ETEC H10407 adhesion to mucin-agar layer
As the gut mucus layer is critical in limiting contact between
host and enteric pathogens (Linden et al. 2008), the ability of
ETEC H10407 to adhere to a mucin-agar layer and the antag-
onistic effect of S. cerevisiaeCNCM I-3856were assessed in a
next step. In preliminary tests, we evaluated the effect of in-
cubation times (60, 90, and 120 min) on ETEC adhesion to
mucin-agar and showed that the maximal percentage of ad-
herent bacteria was obtained as soon as 60 min (data not
shown). Therefore, 1 h incubation was chosen for later exper-
iments. The probiotic yeast was only slightly adherent (less
than 4% adhesion, data not shown). In sharp contrast, ETEC
highly adhered to the mucin-agar layer with percentages of
adhesion of 51 ± 6% (n = 3) (Fig. 1e). When the probiotic
yeast was added, the adhesion was significantly reduced with
residual percentages of 35 ± 11% (p < 0.01, n = 3).
Interestingly, adhesion of the pathogen was found to be
mucin-dependent as the negative control incubation with agar
alone (no mucin) resulted only in 1.5 ± 1.2% of adherent
bacteria.
Pre-incubation with S. cerevisiae CNCM I-3856
reduces ETEC H10407 adhesion to Caco-2/TC7
intestinal cells in a dose-dependent manner
Adhesion to host tissue surfaces is another fundamental step in
the infection process of enteric pathogens. In this study, we
therefore tested if S. cerevisiae CNCM I-3856 can modulate
in vitro adhesion of ETEC H10407 to Caco-2/TC7 human
intestinal cells. The probiotic yeast was added at different
concentrations to intestinal cells through different treatment
modalities (pre, co-, and post-incubation in Fig. 2a–c, respec-
tively). S. cerevisiae CNCM I-3856 only slightly adhered to
intestinal epithelial cells (less than 3% adhesion, data not
shown). Adhesion of ETEC without yeast was assigned as
100%. ETEC residual adhesion was unchanged (except for
concentrations of 106 yeasts/ml, p < 0.05) when S. cerevisiae
CNCM I-3856 was post-incubated with the pathogen (Fig.
2c). In co-incubation experiments, ETEC adhesion tended to
reduce with increasing doses of probiotic, but this effect was
only significant at the highest concentration of 107 yeasts/ml
(residual adhesion of 38 ± 4%, n = 3) (Fig. 2b). The greatest
impact of the probiotic yeast was observed during pre-
incubation assays (Fig. 2a). ETEC adhesion was significantly
reduced in a dose-dependent manner from 106 to 107 yeasts/
ml (p < 0.05). At the highest probiotic dose, residual adhesion
was very low (6 ± 3% p < 0.01). Thus, prophylactic strategy
seems to be the most effective one to limit ETEC H10407
adhesion to Caco-2/TC7 cells.
Pre-incubation with S. cerevisiae CNCM I-3856
decreases IL-8 production in a dose-dependent
manner and LT production in ETEC-infected
Caco-2/TC7 intestinal cells
ETEC infection may elicit a mild inflammatory response as
the result of pathogen interactions with host epithelial cells
(Mercado et al. 2011). In the present study, we confirmed that
ETEC H10407 induced secretion by Caco-2/TC7 intestinal
cells of the interleukin-8 (IL-8) pro-inflammatory cytokine
(Fig. 3). For a better understanding of the immunomodulatory
potential of S. cerevisiae CNCM I-3856, the ability of a 3 h
pre-treatment with probiotic to reduce IL-8 production by
ETEC-infected cells was investigated. Figure 3 shows that S.
cerevisiae CNCM I-3856 effectively inhibited IL-8 produc-
tion in a dose-dependent manner, from 106 yeasts/ml (p
< 0.05). At the highest probiotic dose (107 yeasts/ml), IL-8
production was reduced by 97% (20 ± 19 vs 692 ± 352 pg/ml).
LT production was also measured in supernatants from Caco-
2/TC7 cultures (data not shown). Under untreated conditions,
LT was found only after an overnight ETEC infection at a
concentration of 10 ± 2 pg/ml. This suggests that 3 h infection
was not enough to induce enterotoxin production in our ex-
perimental conditions. When the probiotic was added, what-
ever the dose, LT amounts fell under the detection limit of the
ELISA kit (p < 0.01). This result confirms the inhibitory effect
of S. cerevisiae CNCM I-3856 on LT production already ob-
served in LB media.
In vitro digestion in the gastrointestinal TIM model
does not impair S. cerevisiae CNCM I-3856 ability
to inhibit ETEC adhesion to Caco-2/TC7 intestinal cells
One major challenge for probiotics is to remain viable and
keep their antagonistic properties in the stringent conditions
found in the human gut. Then, the effect of transit through the
upper human gastrointestinal tract (as simulated by the TIM
model) on S. cerevisiae CNCM I-3856 viability and anti-
adhesive property was assessed. Yeast survival percentages
in the TIM ileal effluents are shown in Fig. 4a. The curve
obtained for S. cerevisiae CNCM I-3856 perfectly fits that of
the non-absorbable transit marker, showing that the probiotic
yeast was not impacted by gastrointestinal stresses such as
acid pH in the stomach or bile salts in the small intestine. At
the end of digestion, a global survival percentage of 94.8 ±
4.9% was found, confirming the high resistance of S.
cerevisiae CNCM I-3856 to human gastrointestinal condi-
tions. In a second stage, in order to assess the effect of
in vitro digestion on yeast anti-adhesive properties, the whole
content of the ileal compartment was collected at 120 min,
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washed to remove digestive secretions, and inoculated onto
Caco-2/TC7 intestinal cells at different concentrations. ETEC
residual adhesion to epithelial cells was determined after 3 h
pre-incubation with the probiotic and 3 h infection at MOI
100, based on the results obtained in Fig. 2. As previously
observed with non-digested yeast (Fig. 2a and Fig. 4b), anti-
adhesive properties of digested and washed S. cerevisiae
CNCM I-3856 remained effective from a concentration of
106 yeasts/ml (p < 0.01). Whatever the probiotic dose,
ETEC residual adhesion was similar for non-digested, non-
digested/washed, or digested/washed cells, suggesting that
gastrointestinal passage does not impair the ability of S.
cerevisiae CNCM I-3856 to inhibit ETEC adhesion to epithe-
lial intestinal cells.
S. cerevisiae CNCM I-3856 reduces ETEC colonization
in streptomycin-treated mice
Finally, we used an in vivo model of ETEC infection in ICR
mice to examine the ability of a 3-day pre-treatment with S.
cerevisiae CNCM I-3856 to reduce bacterial colonization.
Administration of the yeast significantly reduced weight loss
associated with ETEC infection (− 8.1 ± 3.2% vs − 12.8 ±
4.4%, p < 0.05), as shown in Fig. 5a. The number of ETEC
bacteria in mice feces (Fig. 5b) as well as the number of
colonic mucosa-associated ETEC bacteria (Fig. 5c) tended
to decrease with probiotic treatment, but the differences were
not found to be significant (182,000 vs 9050 bacteria/mg of
feces, p = 0.0745; 6085 vs 251 bacteria/mg of colonic tissue,
p = 0.0530). The most striking effect of the probiotic yeast
was observed in ileal tissues (Fig. 5c) where ETEC was no
more detected in four out of seven mice (p < 0.05).
Discussion
The present study shows for the first time that the probiotic
yeast S. cerevisiae CNCM I-3856 exerts an antagonistic effect
against the prototypical human ETEC strain H10407. Thanks
to a large range of complementary in vitro and in vivo assays,
we tried to describe associated mechanisms of action, in rela-
tion with the three modes of action described for probiotics
Fig. 2 Effect of treatment modalities and S. cerevisiae CNCM I-3856
concentrations on ETEC adhesion to Caco-2/TC7 intestinal cells.
Intestinal cells were infected during 3 h with 5 × 106 CFU/well of
ETEC H10407 (MOI 100). The probiotic was added with different
treatment modalities (pre-, co-, and post-incubation) and doses (105,
106, 5 × 106, and 107 yeasts/ml). a ETEC residual adhesion to Caco-2/
TC7 cells (%) after 3 h pre-incubation with S. cerevisiae CNCM I-3856
(Sc) followed by 3 h infection. b ETEC residual adhesion to Caco-2/TC7
cells (%) when co-incubated 3 h with Sc. c ETEC residual adhesion to
Caco-2/TC7 cells (%) after 3 h infection, wash, and 3 h post-incubation
with Sc. The data represent the means ± SD of three independent
replicates. ETEC+Sc statistically different from ETEC at p < 0.05 (*) or
p < 0.01 (**)
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against enteric pathogens (Cordonnier et al. 2017; Preidis
et al. 2011): (i) direct antagonism defined as probiotic inhibi-
tion of pathogen growth or downregulation of the expression
of virulence genes, such as adhesins or toxins required for
pathogenesis; (ii) competitive exclusion where probiotics alter
the microenvironment to prevent pathogens from gaining ac-
cess to their appropriate receptors, limit their attachment, col-
onization, entry or translocation, or improve intestinal barrier
function; (iii) and immunomodulation where probiotics elicit
a variety of responses from immune cells to limit infection and
inflammation.
Direct antagonism
Here, we showed that prophylactic treatment with S.
cerevisiae CNCM I-3856 was able to significantly reduce
ETEC growth in culture media. This was assessed by plating
and confirmed by PMA-qPCR to ensure that the lower num-
ber of culturable ETEC was not due to agglutination (see
below). This work is the first study reporting the growth inhi-
bition of an ETEC strain from human origin by probiotic
yeasts, while previous works only involved Lactobacillus
spp. (Tsai et al. 2008). Inhibition of pathogen growth has been
mainly linked to the ability of probiotics to produce antimi-
crobial compounds. Nevertheless, in contrast to probiotic bac-
teria (particularly lactic acid bacteria), which are known to
produce bacteriocins (Dobson et al. 2012), probiotic yeasts
are rarely known to diffuse specific antagonistic compounds
(Tiago et al. 2012).
In ETEC infections, the secretion of enterotoxins repre-
sents the major virulence trait leading to watery diarrhea. In
the present study, we demonstrated that S. cerevisiae down-
regulated eltB mRNA gene expression and LT enterotoxin
production by ETEC in culture media as well as LT
production in intestinal cells. Only one study by Zhou et al.
(2014) has previously shown a decrease in estA gene expres-
sion (encoding ST enterotoxin) by Lactobacillus reuteri in
piglet intestinal cells. The present work is then the first one
performed with human intestinal epithelial cells and providing
results on both LT toxin production and eltB gene expression.
In addition to a reduction in LT gene expression, we showed
that such a decrease in toxin amounts can be also related to its
removal by the probiotic yeast. This removal might be
explained by toxin degradation or binding to yeast surface.
Similarly, Pothoulakis et al. (1993) have previously shown
that a 54-kDa serine protease from another strain of S.
cerevisiae, S. boulardii, effectively hydrolyzes the toxin A
produced by Clostridium difficile. Brandao et al. (Brandão
et al. 1998) also indicated the presence of a specific receptor
on the surface of S. cerevisiaeW303 able to bind to the chol-
era toxin, which is structurally very close to LT toxin. Lastly,
with regard to gene expression, in a previous study by our
team, we have already shown that S. cerevisiae CNCM-
I3856 is able to decrease stx gene expression encoding for
Shiga-toxins in EHEC, another pathotype of E. coli
(Thévenot et al. 2015). This could be mediated through quo-
rum sensing that has been recently shown to modulate the
expression of important virulence genes in ETEC (Sturbelle
et al. 2015).
Exclusion
Enteric pathogens have evolved a wide range of specific strat-
egies to disseminate through the digestive lumen, cross mucus
layer to reach intestinal epithelial cells, and spread the infec-
tion. For example, it has been recently discovered that ETEC
H10407 produces two mucinase proteins YghJ and EatA (Luo
et al. 2014; Kumar et al. 2014) that degrade intestinal mucins
and should promote bacterial access to enterocytes. It is ac-
knowledged that adhesion of bacteria to host surfaces is a
crucial aspect of colonization as it prevents the mechanical
clearing of pathogens and confers a selective advantage to-
wards bacteria of the endogenous microbiota (Ribet and
Cossart 2015). Probiotics can favor the exclusion of pathogens
by competing for binding sites. Therefore, in a second part of
this work, we investigated the ability of S. cerevisiae CNCM
I-3856 to reduce ETEC colonization in a mice model and
inhibit bacterial adhesion to mucins and intestinal Caco-2/
TC7 cells.
Fig. 3 Effect of pre-incubation with S. cerevisiae CNCM I-3856 at
different concentrations on IL-8 production by ETEC-infected Caco-2/
TC7 intestinal cells. Intestinal cells were pre-incubated with the probiotic
yeast during 3 h at different doses (105, 106, and 107 yeasts/ml). Then,
Caco-2/TC7 cells were infected during 3 h with 5 × 106 CFU/ml (MOI
100) of ETEC H10407. Interleukin-8 (IL-8) concentrations (in pg/ml)
were determined in culture supernatants at the end of assays. Control
experiments were performed without ETEC and probiotic (not infected)
and without probiotic (not treated). The data represent the means ± SD of
three independent replicates. Statistically different from untreated cells
under similar experimental conditions at p < 0.05 (*) or p < 0.01 (**)
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We demonstrated in our model of immunocompetent mice
that S. cerevisiae CNCM I-3856 effectively reduces ETEC ileal
loading. This is the first work reporting the inhibition by a pro-
biotic yeast of ETEC colonization in vivo in animals. Up to date,
only one study has described in a murine model a reduction in
bacterial fecal shedding after oral administration of Lactobacillus
casei, but the intestinal loading of the pathogen was not mea-
sured (Mirnejad et al. 2010). This result is particularly striking as
the ileum is known to be the main site of infection by ETEC in
the human body (Deneke et al. 1983). Interestingly, the tropism
of ETEC for the mice ileum has been also recently confirmed by
using in vivo bioluminescence imaging (Rodea et al. 2017).
In further experiments, we showed that the probiotic S.
cerevisiae reduced the number of adherent bacteria in vitro both
to mucus layer and human intestinal epithelial cells. In the last
case, the effect was found to be dose-dependent and maximized
by a prophylactic treatment. There was no documented study
reporting the inhibition of ETEC adhesion to mucins by
probiotics. On the contrary, anti-adhesive properties of lactic
acid bacteria and probiotic yeast strains have been already ev-
idenced in in vitro cultures of human (Osmanagaoglu et al.
2010, Zhong et al. 2004) and piglet (Badia et al. 2012; Roselli
et al. 2007) intestinal cells. Little is known about the mecha-
nism of inhibition of ETEC adhesion by probiotics. It has been
Fig. 4 Effect of in vitro digestion in the gastrointestinal TIM model on
anti-adhesive properties of S. cerevisiae CNCM I-3856 against ETEC.
Gastrointestinal digestions of probiotic yeasts (initial concentration in the
glass of water was 107 yeasts/ml) were performed in the TIMmodel. a In
a first series of digestion, digestive samples were regularly collected in the
ileal effluents and plated onto selective medium. Probiotic survival
kinetic was expressed in cumulative percentages of intake. At the end
of digestion, cumulative ileal effluents and final gastrointestinal residue
were pooled (Tf). Survival percentages of the probiotic were compared to
those of a non-absorbable transit marker. The data represent the means ±
SD of three independent replicates. b In a second series of digestion, the
whole content of the ileal compartment was recovered at 120 min, and
yeast cells were washed and added to Caco-2/TC7 intestinal cells at
different concentrations (105, 106, 5 × 106, and 107 yeasts/ml). Yeasts
were pre-incubated for 3 h before an additional period of 3 h infection
with ETEC H10407. ETEC residual adhesion to Caco-2/TC7 cells (in %)
was determined. The data represent the means ± SD of three independent
replicates. Statistically different from untreated cells under similar
experimental conditions at p < 0.01 (**) or p < 0.001 (***)
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assumed that probiotics may (i) impede the access of pathogens
to host intestinal tissue by non-specific steric hindrance (partic-
ularly relevant for yeast cells that are 10 times bigger than
bacteria), (ii) stimulate mucin production and thus impair the
adhesion of pathogens to enterocytes, or (iii) block the binding
site of ETEC to mucins or epithelial cells by receptor competi-
tion (Turner et al. 2006). In accordance with previous studies on
various strains of S. cerevisiae (Klingberg et al. 2008), we
found that our probiotic yeast was slightly adherent to both
mucus and intestinal epithelial cells, making unlikely the adhe-
sive competition between the yeast and ETEC. We further in-
vestigated the ability of S. cerevisiae CNCM I-3856 to trap
ETEC cells at their surface. We showed that the probiotic yeast
effectively agglutinates the human ETEC strain H10407, as it
has been previously observed by Zanello et al. (2011) for the
pig K88 ETEC strain. Agglutination between ETEC and the
probiotic S. cerevisiae was inhibited by mannose. S. cerevisiae
contains mannan in the outer layer of their cell walls and it has
been shown that ETEC strains express at their surface
mannose-sensitive (type 1) fimbrial lectins (Knutton et al.
1984). We therefore propose that ETEC bind to the mannan
on the surface of yeast cells through type 1 fimbriae, thereby
limiting interactions with mannose residues from mucins or
intestinal epithelial cells. A very recent study by Sheikh et al.
(2017) confirms our hypothesis. The authors have shown that
fimH ETEC mutants (with no type 1 pili activity) were unable
to agglutinate yeast and have a reduced ability to adhere to
intestinal epithelial cells. Interestingly, fimH mutants were also
impaired in delivery of both LT and ST toxins.
Overall, we hypothesized that the reduced ETEC coloniza-
tion observed in mice after the yeast treatment might be
correlated to an inhibition of ETEC adhesion to mucin
and intestinal epithelial cells, as a possible consequence
of probiotic-pathogen agglutination. It might be also relat-
ed to (i) the reduction of ETEC growth which in turn
diminishes the number of adherent ETEC or to (ii) the
decrease in LT toxin production due to direct antagonism,
as Allen et al. (2006) have already shown that the entero-
toxin provides a significant advantage in colonization of
the small intestine.
Immunomodulation
The epithelium is a crucial regulator of intestinal immune
homeostasis and the modulation of inflammatory responses
is thought to be an important mechanism by which probiotics
modify the outcome of enteric infections. The synthesis and
secretion of pro-inflammatory cytokines are initiated by bac-
terial interactions with cellular receptors such as toll-like
receptors (TLR) (Mongensen 2009) and orchestrated by the
well-known inflammatory signaling pathways nuclear factor
kappa B (NF-κB), extracellular signal-regulated kinases
(ERK1/2), or p38 mitogen-activated protein kinase (p38-
MAPK) (Schmitz et al. 2011). ETEC induce a mild inflam-
matory response (Pawlowski et al. 2009) and IL-1β, IL-8,
IL-6, and TNF-α pro-inflammatory cytokines were detected
in fecal samples of infected patients (Mercado et al. 2011;
Long et al. 2010). Here, we showed that pre-incubation with
S. cerevisiae CNCM I-3856 inhibited in a dose-dependent
manner IL-8 production by ETEC-infected human intestinal
cells. Our results are in accordance with the work from
Klingspor et al. (2015) who demonstrated that IL-8
Fig. 5 Effect of S. cerevisiae CNCM I-3856 on ETEC colonization in
ICR mice. Five to seven ICR mice were forced-fed 3 days with 5 ×
107 yeasts/day before infection with ETEC H10407 (108 CFU). a Body
weight loss (in%) of mice at day 4 (24 h after ETEC challenge) compared
to day 1. The data represent the means ± SEM of five (ETEC) to seven
(ETEC+Sc) mice per group. ETEC+Sc statistically different from ETEC
at p < 0.05 (*). bNumber of ETEC bacteria at day 4 (in CFU/mg of feces)
in feces of infected mice treated or not with Sc. Individual results are
indicated by each point and lines represent medians. c Number of
ETEC bacteria at day 4 (in CFU/mg of tissue) associated to the ileal or
colonic mucosa of infected mice treated or not with Sc. Individual results
are indicated by each point and lines represent medians. ETEC+Sc
statistically different from ETEC at p < 0.05 (*)
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expression was considerably increased in ETEC-infected hu-
man Caco-2 cells and that of Zanello et al. (2011) who
showed in infected porcine epithelial intestinal cells (IPEC-
J2) that S. cerevisiae CNCM I-3856 inhibited IL-8 gene ex-
pression. The effect of the probiotic yeast has been linked to
its ability to decrease ERK1/2 and p38 MAPK phosphoryla-
tion. Another hypothesis is that the yeast could interfere with
TLR signaling as previously described for Lactobacillus
rhamnosus by Li et al. (2012). Lastly, the decrease in IL-8
concentration could be related to a lower number of bacteria
adhered to epithelial cells, as described above, or to IL-8
degradation by the yeast or binding to its cell surface.
Nevertheless, this last hypothesis seems unlikely, as only
one previous study has shown in a murine colitis model that
a probiotic strain of Lactobacillus was able to degrade IP-10
chemokine through the secretion of a protease called
lactocepin (Von Schillde et al. 2012).
Taken together, our results suggest that S. cerevisiae
CNCM I-3856 seems to exert an anti-infectious activity
against the human reference strain ETEC H10407 through a
multi-targeted approach, namely inhibition of bacterial growth
and toxin production, reduction of adhesion to mucins and
intestinal epithelial cells, and suppression of ETEC-induced
inflammation (Fig. 6). We also highlighted that the most effi-
cient way to administer the probiotic treatment would be the
use of prophylactic measures. In vivo studies in humans have
already shown that S. cerevisiae CNCM I-3856 significantly
improved abdominal pain/discomfort and bloating in IBS pa-
tients (Cayzeele-Decherf et al. 2014). Besides, traveler’s diar-
rheas have been associated with a higher risk of developing
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Fig. 6 Overview of S. cerevisiae CNCM I-3856 potential modes of action in ETEC infection. S. cerevisiae CNCM I-3856 exerts inhibitory effects (red
line) against ETEC H10407 through direct antagonism, competitive exclusion, and immunomodulation
IBS (Connor and Riddle 2013). Therefore, S. cerevisiae
CNCM I-3856 may be used not only to prevent ETEC infec-
tions but also associated PI-IBS. Next steps will be dedicated
to the study of probiotic/ETEC interactions in a more complex
and physiologically relevant digestive environment by using
dynamic multi-compartmental models of the human gastroin-
testinal tract, such as the TNO gastrointestinal model (TIM) or
the Simulator of the Human Intestinal Microbial Ecosystem
(SHIME). In particular, for a deeper understanding of the pro-
biotic mode of action, we will investigate how S. cerevisiae
CNCM I-3856 may modulate human gut microbiota and the
subsequent impact on ETEC colonization.
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